The UK has become the first country to approve the shot, which targets omicron alongside the original strain of SARS-CoV-2.
Academic rigor, journalistic flair
Articles on Moderna
Displaying 1 - 20 of 60 articles
It’s natural to have questions about the risks and benefits of COVID vaccines in young children. Here’s what you need to know ahead of Australia’s rollout.
Is it time for a new generation of COVID vaccines? Here’s where the research is at.
On the horizon: A new omicron-focused version of the Moderna vaccine that may offer longer protection and a stronger immune response.
Waiving patent rights on COVID-19 vaccines and drugs is still crucial to ensure access globally, but the waiver on the table at the June World Trade Organization meeting doesn’t do the job.
Boosters and vaccinating children mean we’re relying on two pharmaceutical companies to supply Australia’s COVID vaccines. That needs to change.
Moves by Moderna and BioNTech to make vaccines themselves in African countries signal that the companies aren’t considering licensing its technology to a third party for local manufacture.
New research sheds light on how Canadian researchers developed a key component of the mRNA COVID-19 vaccines but failed to share it with the world
Parents can now choose Moderna to vaccinate their children against COVID. So how effective is it, and how does it compare with Pfizer?
Fewer people reported needing to miss work after their booster, compared to their second dose.
The new omicron variant of coronavirus has a number of mutations that may require manufacturers to update vaccines. The unique attributes of mRNA vaccines make updating them fast and easy.
Moderna claims its scientists alone invented the mRNA sequence used to produce its COVID-19 vaccine. The US government, which helped fund the drug, disagrees.
Properly engaged and monitored, Nigeria’s private sector can do more in COVID vaccination exercise.
Protection from infection wanes over time. So boosters will offer extra protection and hopefully reduce the spread of the virus even further.
As boosters are authorized for all three COVID-19 shots available in the US, the ability to swap out vaccine types looks to be a boon to the immune system.
There are very few situations where someone can’t have a COVID vaccine for medical reasons.
A medical student answers questions he gets asked at a COVID-19 vaccine clinic: Efficacy versus real-world effectiveness, immune response and how the mRNA vaccines compare to vaccines already in wide use.
University of Canberra Professorial Fellow Michelle Grattan and University of Canberra Associate Professor Caroline Fisher discuss the week in politics.
Doses of the Moderna vaccine will be available in Australia from mid-September. So if you’re in an eligible group you could be offered either Pfizer or Moderna. Here’s how they compare.
The Moderna vaccine has been provisionally approved by the Therapeutic Goods Administration for use in Australia, with one million doses due in the second half of September, which will go to pharmacies.
Top contributors
-
Professor of Medicine, University of Virginia
-
Project Coordinator & Staff Scientist, Vanderbilt University Medical Center, Vanderbilt University
-
Associate Professor and ARC Future Fellow, The University of Western Australia
-
Professor of Microbiology, School of Medicine, University of Washington
-
Professorial Fellow, University of Canberra
-
Professor of Law, Villanova School of Law
-
Paediatrician at the Royal Childrens Hospital and Associate Professor and Clinician Scientist, University of Melbourne and MCRI, Murdoch Children's Research Institute
-
Associate Professor, Discipline of Childhood and Adolescent Health, University of Sydney
-
Professor Emeritus of Health Policy and Management, York University, Canada
-
Assistant Professor, School of Professional Communication, Toronto Metropolitan University
-
Leader, Science Communication Teaching Program, The University of Melbourne
-
Professor of Immunology and Pro Vice-Chancellor, Research Partnerships, Victoria University
-
Professor and Distinguished Research Chair, Globalization and Health Equity, L’Université d’Ottawa/University of Ottawa
-
Professor of Technology Management, University of Pretoria
-
Fellow, Nigerian Academy of Science
